4 most recent filings and news items mentioning AZTR. Updated every 60 seconds.
RestructuringJun 17, 2026Positive
CEO Francisco Salva outlined strategic reorientation initiatives following a $10.5M financing in March, expanding beyond precision dermatology into cosmetic ingredients and biotech tools. The company aims to leverage microbial genetic engineering technology to participate in larg
View filing at SEC.gov →
RegulatoryJun 16, 2026Neutral
Azitra increased total authorized shares from an unstated prior amount to 760M shares, comprising 750M common shares and 10M preferred shares. The amendment provides greater flexibility for future equity issuances and capital structure management.
View filing at SEC.gov →
OtherJun 4, 2026Negative
Azitra's 2026 Annual Meeting was adjourned from June 4 to June 15 because only 17% of shares were represented, below the required 33.3% quorum threshold. The reconvened virtual meeting allows additional time for stockholder participation and voting on company proposals.
View filing at SEC.gov →
OtherMay 27, 2026Negative
Azitra announced it will convene its 2026 annual stockholder meeting on June 4, 2026, then immediately adjourn and reconvene on June 15, 2026, citing a minor administrative delay in mailing proxy materials. The postponement allows additional time for stockholders to receive and s
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.